Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim or Filgrastim with CHOP-R in Non-Hodgkin's Lymphoma
NCT00117897Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2002
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, randomised, open-label trial in Non-Hodgkin lymphoma (NHL) comparing Pegfilgrastim Arm with Filgrastim Arm (2 arms). Primary endpoint: Ability of pegfilgrastim or Filgrastim to support planned dose on time (PDOT) application of CHOP chemotherapy with Rituximab. Started Jul 2002; status: completed.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00117897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117897.